Comparison of BCG Tokyo172 Strain Induction Therapy Between Low Dose and Standard Dose for Non-Muscle Invasive Bladder Cancer: Intravesical Instillation of BCG Tokyo172 Strain
Objectives: The aim of this study was to identify factors that predict recurrence by comparing low-dose and standard-dose Bacillus Calmette-Guérin (BCG) induction therapy in patients with non-muscle invasive bladder cancer (NMIBC). Methods: A total of 273 consecutive NMIBC patients who received low-...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/13/1/174 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832589012961853440 |
|---|---|
| author | Hideyuki Isobe Fumitaka Shimizu Takeshi Ieda So Nakamura Naoko Takazawa Hanna Suetsugu Kazunori Kajino Shu Hirai Hisashi Hirano Katsuhito Yuzawa Shigeo Horie |
| author_facet | Hideyuki Isobe Fumitaka Shimizu Takeshi Ieda So Nakamura Naoko Takazawa Hanna Suetsugu Kazunori Kajino Shu Hirai Hisashi Hirano Katsuhito Yuzawa Shigeo Horie |
| author_sort | Hideyuki Isobe |
| collection | DOAJ |
| description | Objectives: The aim of this study was to identify factors that predict recurrence by comparing low-dose and standard-dose Bacillus Calmette-Guérin (BCG) induction therapy in patients with non-muscle invasive bladder cancer (NMIBC). Methods: A total of 273 consecutive NMIBC patients who received low-dose (40 mg) or standard-dose (80 mg) BCG intravesical instillation therapy between January 2004 and December 2023 were analyzed. Recurrence-free survival (RFS) rates were assessed using the Kaplan–Meier method with the log-rank test. Univariate and multivariate Cox proportional hazards regression analyses were used to identify independent predictors of recurrence based on the Club Urológico Español de Tratamiento Oncológico (CUETO) criteria. Results: The log-rank test showed that older age, low BCG dose, number of tumors, and a history of recurrence increased the risk of recurrence significantly. Regarding older patients, recurrence rates were similar between the two dose groups. However, younger patients had significantly lower recurrence rates with standard-dose BCG compared to low-dose BCG. Multiple Cox regression analysis confirmed that older age, low-dose BCG, greater than three tumors, and a history of recurrence were significant predictors of recurrence. Conclusions: In this study, we found that low-dose BCG induction therapy was associated with higher relapse rates compared with standard doses, especially in younger patients. Age-related differences in the immune response to BCG may influence these relapse patterns. |
| format | Article |
| id | doaj-art-db204bb1df7d4f799001473baf08b64b |
| institution | Kabale University |
| issn | 2227-9059 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj-art-db204bb1df7d4f799001473baf08b64b2025-01-24T13:24:16ZengMDPI AGBiomedicines2227-90592025-01-0113117410.3390/biomedicines13010174Comparison of BCG Tokyo172 Strain Induction Therapy Between Low Dose and Standard Dose for Non-Muscle Invasive Bladder Cancer: Intravesical Instillation of BCG Tokyo172 StrainHideyuki Isobe0Fumitaka Shimizu1Takeshi Ieda2So Nakamura3Naoko Takazawa4Hanna Suetsugu5Kazunori Kajino6Shu Hirai7Hisashi Hirano8Katsuhito Yuzawa9Shigeo Horie10Department of Urology, Juntendo Tokyo Koto Geriatric Medical Center, Tokyo 136-0075, JapanDepartment of Urology, Juntendo University Graduate School of Medicine, Tokyo 113-8431, JapanDepartment of Urology, Juntendo University Graduate School of Medicine, Tokyo 113-8431, JapanDepartment of Urology, Juntendo Tokyo Koto Geriatric Medical Center, Tokyo 136-0075, JapanDepartment of Urology, Juntendo Tokyo Koto Geriatric Medical Center, Tokyo 136-0075, JapanDepartment of Urology, Juntendo Tokyo Koto Geriatric Medical Center, Tokyo 136-0075, JapanDepartment of Pathology, Juntendo Tokyo Koto Geriatric Medical Center, Tokyo 136-0075, JapanDepartment of Pathology, Juntendo Tokyo Koto Geriatric Medical Center, Tokyo 136-0075, JapanDepartment of Urology, Otakanomori Hospital, Chiba 277-0863, JapanDepartment of Urology, Juntendo University Graduate School of Medicine, Tokyo 113-8431, JapanDepartment of Urology, Juntendo University Graduate School of Medicine, Tokyo 113-8431, JapanObjectives: The aim of this study was to identify factors that predict recurrence by comparing low-dose and standard-dose Bacillus Calmette-Guérin (BCG) induction therapy in patients with non-muscle invasive bladder cancer (NMIBC). Methods: A total of 273 consecutive NMIBC patients who received low-dose (40 mg) or standard-dose (80 mg) BCG intravesical instillation therapy between January 2004 and December 2023 were analyzed. Recurrence-free survival (RFS) rates were assessed using the Kaplan–Meier method with the log-rank test. Univariate and multivariate Cox proportional hazards regression analyses were used to identify independent predictors of recurrence based on the Club Urológico Español de Tratamiento Oncológico (CUETO) criteria. Results: The log-rank test showed that older age, low BCG dose, number of tumors, and a history of recurrence increased the risk of recurrence significantly. Regarding older patients, recurrence rates were similar between the two dose groups. However, younger patients had significantly lower recurrence rates with standard-dose BCG compared to low-dose BCG. Multiple Cox regression analysis confirmed that older age, low-dose BCG, greater than three tumors, and a history of recurrence were significant predictors of recurrence. Conclusions: In this study, we found that low-dose BCG induction therapy was associated with higher relapse rates compared with standard doses, especially in younger patients. Age-related differences in the immune response to BCG may influence these relapse patterns.https://www.mdpi.com/2227-9059/13/1/174non-muscle invasive bladder cancerlow-dose BCGstandard-dose BCGintravesical induction therapy |
| spellingShingle | Hideyuki Isobe Fumitaka Shimizu Takeshi Ieda So Nakamura Naoko Takazawa Hanna Suetsugu Kazunori Kajino Shu Hirai Hisashi Hirano Katsuhito Yuzawa Shigeo Horie Comparison of BCG Tokyo172 Strain Induction Therapy Between Low Dose and Standard Dose for Non-Muscle Invasive Bladder Cancer: Intravesical Instillation of BCG Tokyo172 Strain Biomedicines non-muscle invasive bladder cancer low-dose BCG standard-dose BCG intravesical induction therapy |
| title | Comparison of BCG Tokyo172 Strain Induction Therapy Between Low Dose and Standard Dose for Non-Muscle Invasive Bladder Cancer: Intravesical Instillation of BCG Tokyo172 Strain |
| title_full | Comparison of BCG Tokyo172 Strain Induction Therapy Between Low Dose and Standard Dose for Non-Muscle Invasive Bladder Cancer: Intravesical Instillation of BCG Tokyo172 Strain |
| title_fullStr | Comparison of BCG Tokyo172 Strain Induction Therapy Between Low Dose and Standard Dose for Non-Muscle Invasive Bladder Cancer: Intravesical Instillation of BCG Tokyo172 Strain |
| title_full_unstemmed | Comparison of BCG Tokyo172 Strain Induction Therapy Between Low Dose and Standard Dose for Non-Muscle Invasive Bladder Cancer: Intravesical Instillation of BCG Tokyo172 Strain |
| title_short | Comparison of BCG Tokyo172 Strain Induction Therapy Between Low Dose and Standard Dose for Non-Muscle Invasive Bladder Cancer: Intravesical Instillation of BCG Tokyo172 Strain |
| title_sort | comparison of bcg tokyo172 strain induction therapy between low dose and standard dose for non muscle invasive bladder cancer intravesical instillation of bcg tokyo172 strain |
| topic | non-muscle invasive bladder cancer low-dose BCG standard-dose BCG intravesical induction therapy |
| url | https://www.mdpi.com/2227-9059/13/1/174 |
| work_keys_str_mv | AT hideyukiisobe comparisonofbcgtokyo172straininductiontherapybetweenlowdoseandstandarddosefornonmuscleinvasivebladdercancerintravesicalinstillationofbcgtokyo172strain AT fumitakashimizu comparisonofbcgtokyo172straininductiontherapybetweenlowdoseandstandarddosefornonmuscleinvasivebladdercancerintravesicalinstillationofbcgtokyo172strain AT takeshiieda comparisonofbcgtokyo172straininductiontherapybetweenlowdoseandstandarddosefornonmuscleinvasivebladdercancerintravesicalinstillationofbcgtokyo172strain AT sonakamura comparisonofbcgtokyo172straininductiontherapybetweenlowdoseandstandarddosefornonmuscleinvasivebladdercancerintravesicalinstillationofbcgtokyo172strain AT naokotakazawa comparisonofbcgtokyo172straininductiontherapybetweenlowdoseandstandarddosefornonmuscleinvasivebladdercancerintravesicalinstillationofbcgtokyo172strain AT hannasuetsugu comparisonofbcgtokyo172straininductiontherapybetweenlowdoseandstandarddosefornonmuscleinvasivebladdercancerintravesicalinstillationofbcgtokyo172strain AT kazunorikajino comparisonofbcgtokyo172straininductiontherapybetweenlowdoseandstandarddosefornonmuscleinvasivebladdercancerintravesicalinstillationofbcgtokyo172strain AT shuhirai comparisonofbcgtokyo172straininductiontherapybetweenlowdoseandstandarddosefornonmuscleinvasivebladdercancerintravesicalinstillationofbcgtokyo172strain AT hisashihirano comparisonofbcgtokyo172straininductiontherapybetweenlowdoseandstandarddosefornonmuscleinvasivebladdercancerintravesicalinstillationofbcgtokyo172strain AT katsuhitoyuzawa comparisonofbcgtokyo172straininductiontherapybetweenlowdoseandstandarddosefornonmuscleinvasivebladdercancerintravesicalinstillationofbcgtokyo172strain AT shigeohorie comparisonofbcgtokyo172straininductiontherapybetweenlowdoseandstandarddosefornonmuscleinvasivebladdercancerintravesicalinstillationofbcgtokyo172strain |